Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity

导致人类系统性自身免疫的免疫细胞和分泌途径

• 批准号: 9906169
• 负责人: Maria Virginia Pascual
• 金额: $ 46.61万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9906169
• 关键词: Address; Adult; Area; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Beds; Bioinformatics; Biological Assay; Biological Markers; Biology; Blood; CD4 Positive T Lymphocytes; CXCR3 gene; Cancer Biology; Cell Compartmentation; Cell physiology; Cells; Child; Child Health; Childhood; Classification; Clinical; Clinical Trials; Clinical Trials Design; Collaborations; Communicable Diseases; Complement; DNA; Data; Dendritic cell activation; Development; Disease; Fibroblasts; Generations; Goals; Heterogeneity; Human; Hypersensitivity; Immune; Immune System Diseases; Immune system; Immunology; In Vitro; Inflammation; Infrastructure; Institutes; International; Knowledge; Lesion; Link; Longitudinal Studies; Lupus Nephritis; Malignant Neoplasms; Medicine; Metabolic; Molecular; Molecular Biology; Monitor; Myelogenous; Myeloid Cells; Neoplasm Metastasis; Nephritis; New York; Pathogenesis; Pathogenicity; Pathologic; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Physiological; Plasma; Population; Recording of previous events; Research; Research Personnel; Resources; Role; Series; Software Engineering; Systemic Lupus Erythematosus; Systemic disease; T-Lymphocyte; T-Lymphocyte Subsets; Technology; Tissues; Translational Research; Work; autoinflammatory; base; cellular targeting; chronic inflammatory disease; cohort; disease heterogeneity; exosome; experience; extracellular; extracellular vesicles; high throughput technology; immunoregulation; insight; intercellular communication; interstitial; multidisciplinary; nanoparticle; new therapeutic target; novel; particle; patient oriented; patient stratification; personalized approach; personalized care; personalized medicine; programs; relapse prediction; response; stem; systemic autoimmune disease; systemic autoimmunity; technological innovation; tool; trafficking; treatment response; tumor; tumor microenvironment; uptake

The Autoimmunity Center of Excellence based at Weill Cornell Medicine (WCM) in New York, NY aims at 1) advancing the knowledge of pathways and mechanisms that contribute to the development and amplification of Human Systemic Autoimmune Diseases (SADs); 2) developing tools and identifying biomarkers to monitor these dysfunctional pathways. Ultimately, we aim to be able to stratify patients towards personalized approaches to treatment. The Center will employ ex vivo and in vitro high throughput technologies and immune profiling to gain insight into the contribution to disease of two major and complementary compartments contributing to systemic disease: Immune Cells and Extra-Cellular Nanoparticles. The appropriate infrastructure is in place to support patient- based studies. In particular, we emphasize the following key conceptual and technological innovations adding to our strengths, that include an established pediatric SLE cohort followed by experienced clinicians with an exceptional record of participation in translational research While the initial focus will be the study of children with Systemic Lupus Erythematosus (SLE), extrapolation of the Center findings to adult SLE as well as other SAD scenarios will be pursued, particularly in the context of the ACE Collaborative efforts. The Drukier Institute for Children’s Health Research at Weill Cornell Medicine has gathered a multidisciplinary team of pediatric basic and patient-oriented investigators with expertise in immunology, autoimmunity, cancer biology, molecular biology, bioinformatics and software engineers, who work together with clinical experts in autoimmunity, cancer, allergy and infectious diseases—from bed-to-bench and bench-to-bed—to understand and treat these diseases. The Institute has also established strong local, national and international collaborations. Dr. Pascual’s team has a long history of productive research in the fields of human autoinflammatory and autoimmune diseases. Dr. Lyden’s group has pioneered the study of exosomes and exomeres, and how these particles horizontally transfer their cargo to recipient cells, thereby acting as vehicles of intercellular communication in both physiological and pathological conditions. The proposed Center is a natural result of the very complementary expertise of these groups and is well-poised to work collaboratively to advance clinical and basic discoveries in the field of human autoimmunity. .

纽约纽约的Weill Cornell Medicine（WCM）的自身免疫卓越中心，目标为1） 促进有助于发展和放大的途径和机制的知识 人类系统性自身免疫性疾病（SADS）； 2）开发工具并识别生物标志物来监视这些工具 功能失调的途径。最终，我们的目标是能够将患者分类为个性化方法 治疗。 该中心将采用离体和体外高吞吐量技术和免疫专长来获得洞察力 对两个主要和互补室的疾病的贡献，这些疾病有助于系统性疾病： 免疫细胞和细胞外纳米颗粒。适当的基础设施支持患者 - 基于研究。特别是，我们强调以下关键概念和技术创新，以增加 我们的优势，包括一个已建立的儿科SLE队列，然后是经验丰富的临床医生 参与转化研究的出色记录 最初的重点是研究全身性红斑狼疮（SLE）的儿童 将追求成人SLE的中心发现以及其他悲伤的情况，特别是在 ACE协作努力。 Weill Cornell Medicine的Drukier儿童健康研究所已收集了多学科 小儿基本和以患者为导向的研究人员具有免疫学专业知识，自身免疫，癌症的专业知识 生物学，分子生物学，生物信息学和软件工程师，与临床专家合作 自身免疫性，癌症，过敏和感染性疾病（从床到板凳和床位）都可以理解 并治疗这些疾病。该研究所还建立了强大的本地，国家和国际 协作。 Pascual博士的团队在人类领域的生产研究历史悠久 自身炎症和自身免疫性疾病。莱顿博士的小组率先研究了外泌体和 异构体，以及这些颗粒如何水平将其货物传递到受体单元，从而充当车辆 在物理和病理条件下的细胞间通信。提议的中心是自然的 这些小组非常完善的专业知识的结果，并竭尽全力合作以促进 人类自身免疫领域的临床和基本发现。 。